EA PHARMA CO., LTD.

Novel Oral α4β7 Integrin Inhibitor NSHO-101 Shows Promise for IBD Treatment in Phase 1 Data

3 months ago

• Ensho Therapeutics' NSHO-101 demonstrates sustained target engagement with once-daily oral dosing, achieving over 95% α4β7 receptor occupancy across 24-hour intervals in healthy volunteers. • The drug shows favorable safety profile with no serious adverse events and maintains selective binding without affecting peripheral blood lymphocyte counts. • Phase 2 clinical trials for ulcerative colitis treatment are planned to begin in early 2025, potentially offering a convenient oral alternative to existing injectable biologics.

Newron Pharmaceuticals Expands Evenamide Reach in Asia with New Licensing Agreements

5 months ago

• Newron Pharmaceuticals has partnered with Myung In Pharm for the development and commercialization of evenamide in South Korea, contributing to a Phase III trial. • EA Pharma, a subsidiary of Eisai, has secured a license agreement with Newron for evenamide in Japan and other Asian territories, providing significant upfront payment. • Evenamide, a novel glutamate modulator, is being developed as an add-on therapy for treatment-resistant schizophrenia, addressing a critical unmet need. • Phase III trials for evenamide are planned to begin in H1 2025, evaluating its efficacy and safety in patients with treatment-resistant schizophrenia.